The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving only a PET/CT positive partial remission (PR) appropriate in the CAR-T cell era?
 
Nirav Niranjan Shah
Stock and Other Ownership Interests - Cell Vault; Cidara Therapeutics; Exelixis; Geron; Oncosec
Honoraria - Miltenyi Biotec
Consulting or Advisory Role - Celgene; Incyte; Juno Therapeutics; Kite, a Gilead company; Verastem
Research Funding - Miltenyi Biotec
Travel, Accommodations, Expenses - Miltenyi Biotec
 
Kwang Woo Ahn
No Relationships to Disclose
 
Carlos Litovich
No Relationships to Disclose
 
Timothy Fenske
Honoraria - Adaptive Biotechnologies; AstraZeneca; Genentech; Sanofi; Seagen
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Genentech; Kite, a Gilead company; MorphoSys
Research Funding - Kiowa Kirin; Millennium; Portola Pharmaceuticals; TG Therapeutics
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - ADC Therapeutics; Cellerant Therapeutics; Incyte; Janssen Research & Development; MedImmune; Pharmacyclics; Puma Biotechnology (I); Verastem
Speakers' Bureau - AstraZeneca; Celgene; Genzyme
Research Funding - Astellas Pharma; Genzyme; Genzyme; Otsuka; Spectrum Pharmaceuticals; Takeda